Sumitomo Mitsui Trust Group Inc. lessened its holdings in Personalis, Inc. (NASDAQ:PSNL - Free Report) by 7.5% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 733,313 shares of the company's stock after selling 59,295 shares during the quarter. Sumitomo Mitsui Trust Group Inc. owned 1.04% of Personalis worth $4,239,000 as of its most recent SEC filing.
Other large investors have also recently modified their holdings of the company. IQ EQ FUND MANAGEMENT IRELAND Ltd lifted its stake in shares of Personalis by 42.5% in the 3rd quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd now owns 15,103 shares of the company's stock valued at $81,000 after acquiring an additional 4,504 shares during the last quarter. nVerses Capital LLC bought a new position in shares of Personalis in the 3rd quarter valued at $40,000. SG Americas Securities LLC bought a new position in shares of Personalis in the 4th quarter valued at $63,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Personalis in the 4th quarter valued at $87,000. Finally, International Assets Investment Management LLC lifted its stake in shares of Personalis by 438.0% in the 3rd quarter. International Assets Investment Management LLC now owns 20,982 shares of the company's stock valued at $113,000 after acquiring an additional 17,082 shares during the last quarter. Institutional investors and hedge funds own 61.91% of the company's stock.
Personalis Stock Performance
Shares of PSNL stock traded up $0.52 during mid-day trading on Monday, hitting $5.51. The company's stock had a trading volume of 2,444,710 shares, compared to its average volume of 1,063,075. The company's fifty day simple moving average is $5.26 and its 200-day simple moving average is $4.97. Personalis, Inc. has a 52 week low of $1.13 and a 52 week high of $7.20. The company has a market cap of $389.28 million, a PE ratio of -3.28 and a beta of 1.73.
Analyst Ratings Changes
Several research analysts recently issued reports on PSNL shares. HC Wainwright lowered their target price on Personalis from $11.00 to $8.00 and set a "buy" rating for the company in a research report on Monday, January 27th. Lake Street Capital raised their target price on Personalis from $7.00 to $9.00 and gave the stock a "buy" rating in a research report on Wednesday, January 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and set a $7.25 target price on shares of Personalis in a research report on Wednesday, January 8th.
Get Our Latest Stock Analysis on PSNL
Personalis Profile
(
Free Report)
Personalis, Inc develops and markets advanced cancer genomic tests and analytics primarily in the United States, Europe, and the Asia-Pacific. Its tests and analytics are used by pharmaceutical companies for translational research, biomarker discovery, and development of personalized cancer therapies, as well as advanced tests are used by physicians to detect cancer recurrence, monitor cancer evolution, and uncover insights for therapy selection.
Further Reading
Before you consider Personalis, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Personalis wasn't on the list.
While Personalis currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
